![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Dr. Reddy's Laboratories Limited Hyderabad In, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
One of their significant offerings is Naproxen sodium, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2008-068 - Rev 03
This Chemical Type CEP, issued on June 21, 2019, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1702 associated with this CEP further emphasizes